Search
Coagulation Factor IX (Recombinant)
go.drugbank.com/drugs/DB00100Approvedmedium that is then processed and purified for use as a pharmaceutical agent. … Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B).
Products: BeneFIX Powder and Solvent for Solution for Injection 250iu/vial, BeneFIX Powder and Solvent for Solution for Injection 1000iu/vialRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalFood and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval. … Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S.
Categories: Antivirals used in combination for the treatment of HIV infections, Antivirals for Systemic UseGuanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Synonyms: 2-(1-N,N-Heptamethyleneimino)ethylguanidine, N-(2-Perhydroazocin-1-ylethyl)guanidineDinutuximab
go.drugbank.com/drugs/DB09077ApprovedInvestigationalIt is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly
Influenza B virus B/Maryland/15/2016 BX-69A antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14559ApprovedInvestigationalInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Efluelda Tetra Injektionssuspension in einer FertigspritzePlicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Categories: Compounds used in a research, industrial, or household settingEculizumab
go.drugbank.com/drugs/DB01257ApprovedInvestigational[L6919] In Q1 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion of two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria … [L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007.
Products: Soliris Concentrate for Solution for Infusion 300mg/vial, Soliris 10mg/ml Concentrate for Solution for InfusionTrastuzumab emtansine
go.drugbank.com/drugs/DB05773ApprovedInvestigationalTrastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic … Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL, KADCYLA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 160MG/VIALXenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigational[A255183] In December 2022, the FDA approved the use of hyperpolarized Xe-129 for use with MRI for the evaluation of lung ventilation. … Hyperpolarized Xenon-129 (Xe-129) is a contrast agent used in the lung's clinical magnetic resonance imaging (MRI).
Influenza B virus B/Phuket/3073/2013 recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB10779ApprovedInvestigationalInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.
Mixtures: Fluarix Tetra Injektionssuspension in einer Fertigspritze